Cargando…
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Prima...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944709/ https://www.ncbi.nlm.nih.gov/pubmed/35326808 http://dx.doi.org/10.3390/antibiotics11030345 |
_version_ | 1784673786987020288 |
---|---|
author | Ong, Sean W. X. Ren, Dongdong Lee, Pei Hua Sutjipto, Stephanie Dugan, Christopher Khoo, Bo Yan Tay, Jun Xin Vasoo, Shawn Young, Barnaby E. Lye, David C. |
author_facet | Ong, Sean W. X. Ren, Dongdong Lee, Pei Hua Sutjipto, Stephanie Dugan, Christopher Khoo, Bo Yan Tay, Jun Xin Vasoo, Shawn Young, Barnaby E. Lye, David C. |
author_sort | Ong, Sean W. X. |
collection | PubMed |
description | Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Primary outcome was in-hospital deterioration as defined by a composite of oxygen requirement, intensive care unit (ICU) admission, or mortality within 28 days of admission. Ninety-four out of 410 COVID-19 inpatients were included in the final analysis, of whom 19 (20.2%) received early treatment with sotrovimab. The median age was 73 years (IQR 61–83), and 35 (37.2%) were female. Although the treatment group was significantly older and had more comorbidities, there was a lower proportion of progression to oxygen requirement (31.6% vs. 54.7%), ICU admission (10.5% vs. 24.0%), or mortality (5.3% vs. 13.3%). Kaplan–Meier curves showed a significant difference in time to in-hospital deterioration (log-rank test, p = 0.043). Cox proportional hazards model for in-hospital deterioration showed that sotrovimab treatment was protective (hazard ratio, 0.41; 95% CI, 0.17–0.99; p = 0.047) after adjustment for baseline ISARIC deterioration score. Our findings support the use of sotrovimab for early treatment in hospitalized patients with mild-to-moderate COVID-19 at a high risk of disease progression. |
format | Online Article Text |
id | pubmed-8944709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89447092022-03-25 Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study Ong, Sean W. X. Ren, Dongdong Lee, Pei Hua Sutjipto, Stephanie Dugan, Christopher Khoo, Bo Yan Tay, Jun Xin Vasoo, Shawn Young, Barnaby E. Lye, David C. Antibiotics (Basel) Article Data on use of monoclonal antibodies (mAbs) in hospitalized patients are limited. In this cross-sectional study, we evaluated the use of mAbs for early treatment of unvaccinated hospitalized patients with mild-to-moderate COVID-19. All inpatients at our center were screened on 27 October 2021. Primary outcome was in-hospital deterioration as defined by a composite of oxygen requirement, intensive care unit (ICU) admission, or mortality within 28 days of admission. Ninety-four out of 410 COVID-19 inpatients were included in the final analysis, of whom 19 (20.2%) received early treatment with sotrovimab. The median age was 73 years (IQR 61–83), and 35 (37.2%) were female. Although the treatment group was significantly older and had more comorbidities, there was a lower proportion of progression to oxygen requirement (31.6% vs. 54.7%), ICU admission (10.5% vs. 24.0%), or mortality (5.3% vs. 13.3%). Kaplan–Meier curves showed a significant difference in time to in-hospital deterioration (log-rank test, p = 0.043). Cox proportional hazards model for in-hospital deterioration showed that sotrovimab treatment was protective (hazard ratio, 0.41; 95% CI, 0.17–0.99; p = 0.047) after adjustment for baseline ISARIC deterioration score. Our findings support the use of sotrovimab for early treatment in hospitalized patients with mild-to-moderate COVID-19 at a high risk of disease progression. MDPI 2022-03-05 /pmc/articles/PMC8944709/ /pubmed/35326808 http://dx.doi.org/10.3390/antibiotics11030345 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ong, Sean W. X. Ren, Dongdong Lee, Pei Hua Sutjipto, Stephanie Dugan, Christopher Khoo, Bo Yan Tay, Jun Xin Vasoo, Shawn Young, Barnaby E. Lye, David C. Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title_full | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title_fullStr | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title_full_unstemmed | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title_short | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
title_sort | real-world use of sotrovimab for pre-emptive treatment in high-risk hospitalized covid-19 patients: an observational cross-sectional study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944709/ https://www.ncbi.nlm.nih.gov/pubmed/35326808 http://dx.doi.org/10.3390/antibiotics11030345 |
work_keys_str_mv | AT ongseanwx realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT rendongdong realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT leepeihua realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT sutjiptostephanie realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT duganchristopher realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT khooboyan realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT tayjunxin realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT vasooshawn realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT youngbarnabye realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy AT lyedavidc realworlduseofsotrovimabforpreemptivetreatmentinhighriskhospitalizedcovid19patientsanobservationalcrosssectionalstudy |